FABP4 and acute lymphoblastic leukemia: Further longitudinal, prospective analyses of the A-FABP and E-FABP levels in ALL survivors and their potential role as the biomarkers in the pathogenesis of overweight, insulin resistance, and cardiovascular complications remain to be performed.